DLL3 and cancer: Moreover, the tri-specific DLL3-targeting T-cell engager [130], which additionally targets the albumin binding domain to extend its half-life, is currently undergoing phase I / II clinical trials (NCT04471727) in patients with DLL3-associated cancers.